Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02
2025-11-06 07:55:30 ET
More on Neumora Therapeutics
- Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs - Slideshow
- Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript
- Neumora to initiate phase 1 study of oral obesity pill
- Seeking Alpha’s Quant Rating on Neumora Therapeutics
- Historical earnings data for Neumora Therapeutics
Read the full article on Seeking Alpha
For further details see:
Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02NASDAQ: NMRA
NMRA Trading
-0.67% G/L:
$2.975 Last:
548,324 Volume:
$2.96 Open:



